Treatment Strategy for Advanced Non-small-cell Lung Cancer with Interstitial Lung Disease

DOI Web Site 26 References
  • Nokihara Hiroshi
    Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University
  • Nishioka Yasuhiko
    Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University

Bibliographic Information

Other Title
  • 間質性肺炎合併非小細胞肺癌の治療戦略

Search this article

Abstract

<p>Recently, angiogenesis inhibitors, inhibitors against driver mutation, and immune checkpoint inhibitors have been used widely for the treatment of advanced non-small-cell lung cancer (NSCLC) in clinical practice. Although interstitial lung disease (ILD) frequently occurs with lung cancer, the use of anticancer drugs for NSCLC with preexisting ILD is limited because patients with ILD have a risk of drug-related acute exacerbation of ILD. There is little information on the efficacy and safety of angiogenesis inhibitors or immune checkpoint inhibitors for NSCLC with ILD, so the efficacy and safety of treatment with angiogenesis inhibitors or immune checkpoint inhibitors has become a clinical question. In recent years, several prospective clinical trials of anticancer drugs for advanced NSCLC with ILD have been conducted, and the results have been reported. We herein review the results of clinical trials and discuss treatment strategies using anticancer drug for NSCLC with preexisting ILD.</p>

Journal

  • Haigan

    Haigan 60 (2), 74-80, 2020-04-20

    The Japan Lung Cancer Society

References(26)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top